Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276444 | 0.90 | NOTUM (0.50) | NOTUMCNR2HTR2CHTR2BADRB1 | |
| SCHEMBL28212135 | 0.83 | HTR7 (0.46) | NOTUMHTR2CADRB1ALOX5ALDH1A1 | |
| SCHEMBL12905304 | 0.80 | NOTUM (0.53) | NOTUMCNR2HTR2CHTR2BADRB1 | |
| SCHEMBL13462411 | 0.79 | S1PR1 (0.37) | NOTUMKDM4EALDH1A1GAAMAPT | |
| SCHEMBL23067856 | 0.78 | NOTUM (0.50) | NOTUMCNR2HTR2CHTR2BADRB1 | |
| SCHEMBL2625772 | 0.78 | NOTUM (0.57) | NOTUMHTR2CADRB1DRD2DRD4 | |
| SCHEMBL2625776 | 0.78 | NOTUM (0.57) | NOTUMDRD4AADATKDM4EALDH1A1 | |
| SCHEMBL19391295 | 0.78 | NOTUM (0.59) | NOTUMCNR2HTR2CHTR2BADRB1 | |
| SCHEMBL25044260 | 0.78 | KDM4E (0.35) | NOTUMDRD2KDM4EALDH1A1GAA | |
| SCHEMBL11416314 | 0.78 | NOTUM (0.54) | NOTUMCNR2HTR2CHTR2BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022212538-A1 | DIAZEPANONE-FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022094355-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021093817-A1 | IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021057975-A1 | MUTANT IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | CLN6, MSR1, TPMT | NOTUM 2990/4885CNR2 654/4885HTR2C 2153/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NOTUM 4556/4885CNR2 3750/4885HTR2C 3544/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | NOTUM 3081/4885CNR2 230/4885HTR2C 491/4885 |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | NOTUM 2838/4885CNR2 208/4885HTR2C 1087/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885CNR2 1171/4885HTR2C 1379/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885CNR2 1171/4885HTR2C 1379/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885CNR2 1171/4885HTR2C 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.